13F Holdings
中文EN

CODX Co-Diagnostics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1692415 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY69.1%
TTM net income YoY-47.5%
TTM EPS YoY60.1%
Revenue 3-yr CAGR-43.1%
Net income 3-yr CAGR—

Margins

Gross margin20.3%
Operating margin-5,614.3%
Net margin-5,527.6%
FCF margin-3,165.7%
EBITDA margin-5,504.0%

Returns

ROE-194.5%
ROA-165.0%
ROIC (approx.)-207.8%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets26.3%
Debt / equity0.00x
Current ratio0.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-71.6%
Payout ratio—
Capex / revenue35.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$622,489$3.92M$6.81M$34.22M$97.89M
Cost of revenue$222,377$999,124$4.18M$5.48M$11.57M
Gross profit$400,112$2.92M$2.63M$28.74M$86.31M
R&D expense$19.14M$20.98M$22.96M$17.44M$14.96M
SG&A expense$9.06M$16.16M$14.28M$14.26M$11.55M
Operating income-$50.17M-$40.08M-$42.71M-$26.98M$46.06M
Pretax income-$48.51M-$37.58M-$38.11M-$18.85M$45.64M
Income tax-$1.62M$57,368-$2.78M-$4.61M$8.98M
Net income-$46.90M-$37.64M-$35.33M-$14.24M$36.66M
EBITDA-$49.06M-$38.70M-$41.48M-$25.70M$46.40M
EPS (basic)-35.25-37.22-1.20-0.451.27
EPS (diluted)-35.25-37.22-1.20-0.451.23
Weighted avg. shares (diluted)1.33M1.01M29.35M31.48M29.90M
Balance sheet
Cash & equivalents$11.88M$2.94M$14.92M$22.97M$88.61M
Short-term investments—$26.81M$43.63M$58.29M$1.26M
Receivables$190,375$132,570$303,926$3.45M$20.84M
Inventory$992,397$1.07M$1.66M$5.31M$2.00M
Current assets$13.69M$32.29M$62.14M$92.73M$115.12M
PP&E, net$2.27M$2.76M$3.04M$2.54M$1.93M
Goodwill————$14.71M
Intangibles$7.22M$26.10M$26.40M$26.77M$27.20M
Total assets$24.74M$63.56M$95.32M$123.09M$160.03M
Current liabilities$3.54M$7.32M$5.75M$3.87M$12.60M
Total liabilities$4.11M$9.69M$9.31M$8.57M$25.56M
Shareholders' equity$20.63M$53.88M$85.58M$114.52M$134.48M
Shares outstanding2.10M1.10M31.26M30.87M33.82M
Cash flow statement
Operating cash flow-$29.14M-$29.16M-$22.08M$6.57M$41.08M
Capital expenditure$700,047$748,352$1.37M$1.43M$669,463
Free cash flow-$29.84M-$29.90M-$23.45M$5.14M$40.41M
Investing cash flow$26.27M$17.07M$15.39M-$58.17M$4.10M
Financing cash flow$11.81M$103,914-$1.36M-$14.03M$450,398
Depreciation & amortization$1.11M$1.38M$1.23M$1.28M$335,363
Stock-based compensation$2.25M$5.43M$8.34M$7.54M$5.51M
Share buybacks——$1.36M$14.21M—

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.